Form 4: Twist Bioscience COO Finn Receives 79,785 PSUs

Twist Bioscience's President and COO, Patrick John Finn, reported the acquisition of 79,785 shares of common stock from performance stock units.

Summary

• Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), acquired 79,785 shares of common stock.
• This acquisition resulted from Performance Stock Units (PSUs) where target criteria were determined to have been met on October 28, 2025.
• The transaction price for these shares was $0, indicating they were granted as compensation.
• Following this transaction, Finn beneficially owns 286,280 shares of common stock.
• 60% of these PSUs are still subject to time-based vesting and will vest on October 1, 2026, contingent on continued service or accelerated vesting per the award agreement.

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation event where performance targets were met, indicating positive operational achievement. It's a neutral-to-positive event for the company as it reflects successful goal attainment and executive retention.

Positives

• The reporting person, a key executive, met performance targets, indicating successful achievement of company goals.
• The vesting of PSUs aligns executive incentives with long-term shareholder value.

Negatives

• No direct negatives are apparent from this Form 4 filing, which primarily reports a compensation event.

Risks

• 60% of the acquired PSUs are subject to time-based vesting until October 1, 2026, meaning the full benefit is contingent on continued service.

Future Outlook

60% of the Performance Stock Units are subject to time-based vesting and are scheduled to vest on October 1, 2026, contingent on continued service or acceleration as per the award agreement.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology and synthetic biology industry, where performance-based equity awards are common to incentivize leadership and align their interests with long-term company performance.

Comparison to Industry Standards

• The use of Performance Stock Units (PSUs) as a component of executive compensation is a common practice across the biotechnology and high-growth technology sectors, similar to companies like Illumina, Ginkgo Bioworks, or Moderna, which utilize equity awards tied to specific performance metrics and time-based vesting schedules.
• The vesting schedule, with a portion subject to future time-based vesting, is typical for retaining key executives and ensuring long-term commitment, mirroring structures seen in peer companies' compensation plans.

Stakeholder Impact

• Shareholders: The vesting of PSUs aligns executive incentives with shareholder interests, potentially leading to better long-term performance. It also represents a dilution event, though typically planned for in compensation pools.
• Employees: Demonstrates the company's commitment to performance-based compensation for its leadership.

Next Steps

• Continued service by Patrick John Finn to ensure the vesting of the remaining 60% of PSUs on October 1, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event where performance targets for PSUs were met. While it indicates successful operational achievement and aligns executive incentives, it does not present new information that would fundamentally alter the investment thesis for Twist Bioscience. Therefore, a 'hold' recommendation is appropriate as it confirms ongoing operations without providing a catalyst for significant re-evaluation.

Keywords

Twist Bioscience, TWST, Form 4, Insider Trading, Performance Stock Units, PSUs, Executive Compensation, Stock Grant, Patrick John Finn